Ligand signs deal with CURx to develop Captisol-enabled topiramate injection

Ligand Pharmaceuticals has signed a licensing deal with CURx Pharmaceuticals to develop and commercialise its Captisol-enabled topiramate injection to treat partial onset or primary generalized tonic-clonic seizures in hospitalised epilepsy patients.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news